The WHO initially recommended hepatitis B vaccination only in countries with high incidence of hepatocellular carcinoma (HCC), the species of liver cancer that the vaccine promises to abolish. Since HCC is rare in India, the country did not qualify under WHO’s initial criteria, which recommended the vaccine only in nations with significant HCC. WHO’s policy meant the vaccine manufacturers would lose a market of 1.3 billion people.
